5,295 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by MGO One Seven LLC

MGO One Seven LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 5,295 shares of the medical device company's stock, valued at approximately $412,000.

Other large investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC increased its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC increased its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DXCM shares. Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Mizuho started coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Stock Down 1.6 %

NASDAQ:DXCM traded down $1.12 on Thursday, hitting $70.26. The stock had a trading volume of 6,865,096 shares, compared to its average volume of 4,222,913. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $27.55 billion, a PE ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.50. The business's fifty day moving average is $72.01 and its 200 day moving average is $76.67.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 EPS. On average, equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares of the company's stock, valued at $7,432,268.76. This trade represents a 10.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock valued at $4,734,384 in the last three months. Corporate insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.